CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.
March 28th 2025
FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer
January 27th 2024Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.
Nubeqa, Hormone Therapy May Reduce Hospitalizations in Prostate Cancer
January 27th 2024Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.
Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer
January 11th 2024Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).